Binds Specifically-identified Amino Acid Sequence Patents (Class 530/387.9)
-
Publication number: 20140274755Abstract: A multi-transmembrane protein antigen includes a polypeptide corresponding to an extracellular loop of the multi-transmembrane protein, the N-terminal and C-terminal of the polypeptide being fixed on a solid substrate or the N-terminal and C-terminal being attached to both ends of a linker to form a cyclic structure, an antibody specifically binding to the antigen or an antigen-binding fragment thereof, and a method for screening an antibody specifically binding to the antigen. The present invention may be usefully employed for effective production of antibodies for multi-transmembrane proteins that play important roles in disease-related phenomena such as cell signaling.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: REFERENCE BIOLABS INC.Inventors: Young Kee SHIN, Young-Deug KIM, Jun Young CHOI, Myung Seok LEE
-
Publication number: 20140271690Abstract: The present disclosure is directed to individual A? peptide immunogen constructs, peptide compositions comprising these A? peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these A? peptide immunogen constructs, with the individual A? peptide immunogen constructs having the N-terminus of the A? peptide as the B cell (B) epitopes linked through spacer residue(s) to heterologous T helper cell (Th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the N-terminus of the A? peptide offering protective immune responses to patients at risk for, or with, Alzheimer's Disease.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: UNITED BIOMEDICAL, INC.Inventor: Chang Yi Wang
-
Publication number: 20140271653Abstract: The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Anne Gurnett-Bander, David Perez-Caballero, Sumathi Sivapalasingam, Xunbao Duan, Douglas MacDonald
-
Publication number: 20140271650Abstract: Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Robert Francis GARRY, Russell B. WILSON
-
Publication number: 20140271652Abstract: Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Institute of Arthritis Research, LLCInventor: Craig D. Scoville
-
Publication number: 20140274882Abstract: Provided herein are methods for detecting an Aspergillus protease in a sample, diagnosing a subject with aspergillosis caused by an Aspergillus infection based on the presence of an Aspergillus protease in a sample, and methods of aspergillosis treatment that incorporate these diagnostic methods. In certain embodiments, the Aspergillus protease is Asp f2, and the Aspergillus infection is caused A. fumigatus, A. flavus, A. versicolor, A. niger, or A. terreus. Also provided herein are antibodies and kits for use in these methods, including novel antibodies specific for Asp f2.Type: ApplicationFiled: March 17, 2014Publication date: September 18, 2014Inventors: Markus KALKUM, Karine BAGRAMYAN, Diana DIAZ-AREVALO, James I. ITO, Sanjeet DADWAL
-
Publication number: 20140271698Abstract: The present invention relates to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) mutant strains having increased stability; compositions containing the strains or antigens derived therefrom; vaccines containing the strains, including killed, attenuated or subunit vaccines; nucleic acids encoding PRRSV polypeptides, polypeptides encoded by the nucleic acids, including antigenic fragments thereof; antibodies which specifically bind to said polypeptides, and methods making and using thereof.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Dianna M. Murphy JORDAN, Brian Thomas MARTINSON, Michael B. ROOF, Eric Martin VAUGHN, Joseph Gilbert VICTORIA
-
Publication number: 20140273015Abstract: The present disclosure relates to binding compounds/antibodies that bind to the second extracellular loop of the human ?1-adrenoreceptor (?1-AR-ECII) that are produced by/obtainable from a host cell/hybridoma with a deposit number selected from the group consisting of DSM ACC3121, DSM ACC3174, DSM ACC3175, DSM ACC3176 and DSM AC-C3177. The binding compounds/antibodies are particularly useful in determination of auto-anti-?1-AR antibodies in an in vitro cell based assay system in order to characterize and to identify auto-antibodies directed against the ?1-AR-ECII in a biological sample. Further aspects of the disclosure are nucleic acid molecules encoding said binding compounds/antibodies, vectors, host cells, methods for producing the binding compounds/antibodies of the disclosure as well as a kit comprising the binding compounds/antibodies of the present disclosure.Type: ApplicationFiled: June 6, 2012Publication date: September 18, 2014Applicant: CORIM- MUN GMBHInventors: Hans-Peter Holthoff, Martin Ungerer, Stefan Zeibig, Martin J. Lohse, Roland Jahns, Valerie Jahns
-
Publication number: 20140271656Abstract: Immunologically active agents are described, including isolated Pneumocystis A 12 protein or polypeptides; immunogenic conjugates containing Pneumocystis A 12 protein or polypeptide of the present invention; antibodies recognizing the Pneumocystis A 12 protein or polypeptide or the immunogenic conjugates of the present invention; and nucleic acid molecules that encode the Pneumocystis A 12 protein or polypeptide of the present invention, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a subject.Type: ApplicationFiled: August 6, 2012Publication date: September 18, 2014Applicant: UNIVERSITY OF ROCHESTERInventors: Francis Gigliotti, Terry W. Wright, Constantine G. Haidaris, Patricia J. Simpson-Haidaris
-
Publication number: 20140271648Abstract: Broadly neutralizing interferon-? and interferon-? antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFN? and IFN?.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Janssen Biotech, Inc.Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
-
Publication number: 20140283224Abstract: The present invention relates to transgenic plants that have increased nitrogen use efficiency, stress tolerance, and/or alleviating a limitation such that yield is increased, or a combination of these and that have been transformed using a novel vector construct including a synthetic isocitrate dehydrogenase (icdh) gene that modulates nitrogen use in plants. The invention also relates to stacking the icdh gene with other exogenous or heterologous genes that modulate nitrogen use in the plant, including a N-acetylglutamate kinase gene. The invention also relates to methods of expressing in plants the nucleic acid molecules corresponding to the nucleic acid sequences that modulate nitrogen use in plants or are modulated by nitrogen conditions.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: Iowa Corn Promotion BoardInventors: James McLaren, Brian Vande Berg
-
Publication number: 20140271629Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins to CHRDL-1. Human, humanized, and chimeric antibodies, as well as fragments and derivatives thereof are further contemplated. Other embodiments include nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, as well as polypeptides, cells, methods of making and using antigen binding proteins, fragments and derivatives thereof.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Inventors: Kevin Christopher CORBIT, Christopher J.R. Paszty
-
Patent number: 8835609Abstract: The invention relates to purinergic receptors, to antibodies and related fragments thereof for binding to said receptors, to production of said antibodies and fragments and to use of said antibodies and fragments for cancer detection and therapy. In particular the antibodies described bind specifically to non-functional P2X7 receptors expressed by live cells.Type: GrantFiled: December 23, 2010Date of Patent: September 16, 2014Assignee: Biosceptre International LimitedInventors: Julian Alexander Barden, Angus Gidley-Baird, Glenn Ronald Pilkington
-
Patent number: 8835608Abstract: An antibody having an antigen binding region capable of binding an epitope located in an extracellular portion of MRP3 and methods of utilizing same are provided. In particular, the invention provides antibodies targeted at a MRP3 antigen present on cells expressing MRP3 and methods useful in detecting or targeting cells expression the MRP3 antigen, as well as kits, nucleic acids, polypeptides, and cells for providing the antibodies.Type: GrantFiled: November 30, 2007Date of Patent: September 16, 2014Assignee: Duke UniversityInventors: Chien-Tsun Kuan, Darell D Bigner
-
Patent number: 8835617Abstract: A nucleic acid is provided which encodes a human TRIM-cyclophilin A fusion sequence encoding a human TRIM-CypA fusion protein which is active as an anti-viral agent, and in particular, as an anti-HIV-1 agent. Also provided is a nucleic acid encoding a polypeptide having both TRIM activity and cyclophilin activity. Also provided is an isolated polynucleotide encoding a human TRIM-CypA fusion protein, or variants thereof retaining the TRIM and cyclophilin A activities. Also provided are compositions thereof, antibodies that specifically bind thereto, and vectors and host cells comprising the nucleic acid or polypeptide. In addition, methods are provided for treating or preventing viral infection, or reducing viral load in a subject comprising administering the nucleic acid, polypeptide, vector, or composition to the subject in an amount effective to treat or prevent the viral infection.Type: GrantFiled: November 6, 2009Date of Patent: September 16, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jeremy Luban, Martha Neagu
-
Publication number: 20140255411Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants a which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: March 18, 2013Publication date: September 11, 2014Applicant: COMPUGEN LTD.Inventors: Zurit LEVINE, Amir TOPORIK, Amit NOVIK, Anat COHEN-DAYAG, Avi ROSENBERG, Cynthia KOIFMAN, Dalit LANDESMAN-MILO, Eve MONTIA, Galit ROTMAN, Liat DASSA, Marina BUBIS, Merav BEIMAN, Ofer LEVY, Sergey NEMZER, Shira WALACH, Shirley SAMEACH- GREENWALD, Tania PERGAM, Yaron KINAR
-
Publication number: 20140255304Abstract: Provided are novel TDP-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: October 26, 2012Publication date: September 11, 2014Applicants: BIOGEN IDEC INTERNALTIONAL NEUROSCIENCE GMBH, UNIVERSITY OF ZURICHInventors: Nitsch Roger, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
-
Publication number: 20140255412Abstract: The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to pharmaceutical compositions comprising an antigenic peptide, particularly an antigenic phopho-peptide mimicking a major pathological phosphor-epitope of protein tau, for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease.Type: ApplicationFiled: September 16, 2013Publication date: September 11, 2014Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Fred Van Leuven
-
Publication number: 20140255389Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: May 29, 2013Publication date: September 11, 2014Applicant: COMPUGEN LTD.Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH- GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
-
Publication number: 20140255302Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: ApplicationFiled: March 28, 2014Publication date: September 11, 2014Applicant: Teva Pharmaceuticals Australia Pty LtdInventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
-
Publication number: 20140256648Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and/or compositions that include any of the peptides or nucleic acids.Type: ApplicationFiled: March 11, 2014Publication date: September 11, 2014Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: Yusuke NAKAMURA, Takuya TSUNODA, Ryuji OHSAWA, Sachiko YOSHIMURA, Tomohisa WATANABE
-
Publication number: 20140255343Abstract: The object of the invention is a DNA vaccine, method of inducing the immune response, antibodies specifically recognising the haemagglutinin H5 of an influenza virus and application of the DNA vaccine. According to the invention, one or two-fold immunisation of hens with DNA vaccine containing a cDNA encoding the modified H5 haemagglutinin HA protein, i.e. with the deletion of the cleavage site between HA subunits (this provides for greater safety of the vaccines). Moreover, the encoding region of the HA is modified in such a way that protein production in the bird cells should achieve maximal yield. The main modification is codon optimisation for the hens and deletion of the site of proteolytic cleavage between subunits HA1 and HA2.Type: ApplicationFiled: September 21, 2012Publication date: September 11, 2014Inventors: Agnieszka Sirko, Anna Gora-Sochacka, Wlodzimierz Zagorski-Ostoja, Anna Stachyra, Roza Sawicka, Boguslaw Szewczyk, Beata Gromadzka, Violetta Saczynska, Katarzyna Florys, Zenon Minta, Krzysztof Smietanka
-
Publication number: 20140256583Abstract: The invention relates to human endogenous retrovirus env (HERV-WL) polypeptides, nucleotide sequences, HERV-WL antibodies, methods to detect cancer, and methods to determine the effectiveness of the treatment of cancer.Type: ApplicationFiled: March 5, 2014Publication date: September 11, 2014Applicant: Rutgers, The State University of New JerseyInventors: Vincent K. Tsiagbe, Yu Li
-
Publication number: 20140255437Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.Type: ApplicationFiled: October 25, 2012Publication date: September 11, 2014Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
-
Antigens Derived from Citrullinated 14-3-3 and Uses Thereof in the Diagnosis of Rheumatoid Arthritis
Publication number: 20140255957Abstract: The present invention provides citrullinated 14-3-3? peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis.Type: ApplicationFiled: October 19, 2012Publication date: September 11, 2014Inventor: Anthony Marotta -
Publication number: 20140255941Abstract: The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence.Type: ApplicationFiled: June 20, 2012Publication date: September 11, 2014Applicant: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Publication number: 20140255414Abstract: Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.Type: ApplicationFiled: May 19, 2014Publication date: September 11, 2014Inventors: Martin Kleinschmidt, Stephan Schilling, Jens-Ulrich Rahfeld, Kristin Ebermann, Hans-Ulrich Demuth
-
Publication number: 20140255951Abstract: The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.Type: ApplicationFiled: February 4, 2014Publication date: September 11, 2014Applicant: Gilead Biologics, Inc.Inventors: Scott Alan MCCAULEY, Hector RODRIGUEZ, Carlos Aurelio GARCIA, Victoria SMITH
-
Publication number: 20140256041Abstract: Disclosed herein are antibodies against GPR49 and uses of such antibodies. The antibodies can be monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of blocking cancer stem cell growth with such antibodies.Type: ApplicationFiled: October 31, 2012Publication date: September 11, 2014Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Weixing Yang, Christilyn Graff
-
Publication number: 20140255415Abstract: The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with axonal degeneration and demyelination.Type: ApplicationFiled: May 19, 2014Publication date: September 11, 2014Applicant: NOVARTIS AGInventors: Marta CORTES-CROS, Ingo Markus KLAGGE, Josef PRASSLER, Adrian Robert WALMSLEY, William Leonard WISHART
-
Publication number: 20140255413Abstract: The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.Type: ApplicationFiled: March 4, 2014Publication date: September 11, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Paul ADAM, Katrin FRIEDBICHLER
-
Publication number: 20140259207Abstract: The present invention is in the field of plant breeding and aphid resistance. More specifically, the invention includes a method for breeding soybean plants containing quantitative trait loci that are associated with resistance to aphids, Aphis glycines. The invention further includes method for monitoring the introgression quantitative trait loci (QTL) conferring aphid resistance into elite germplasm in a breeding program.Type: ApplicationFiled: May 20, 2014Publication date: September 11, 2014Applicants: Monsanto Technology LLC, University of Georgia Research Foundation, Inc.Inventors: Vergel Concibido, James Narvel, Jennifer Yates, Henry Roger Boerma
-
Publication number: 20140255410Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.Type: ApplicationFiled: December 11, 2012Publication date: September 11, 2014Applicant: ABBVIE INC.Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice
-
Patent number: 8829165Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.Type: GrantFiled: April 10, 2013Date of Patent: September 9, 2014Assignee: Amgen, Inc.Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
-
Patent number: 8828389Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: GrantFiled: December 7, 2011Date of Patent: September 9, 2014Assignee: Amorfix Life Sciences Ltd.Inventor: Neil Cashman
-
Publication number: 20140248272Abstract: The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in Treponema spp. isolated from digital dermatitis in cattle. The present invention further relates to antibodies raised against said proteins or fragments thereof, and the use of said proteins in diagnostic methods in which antibodies are detected as a sign of digital dermatitis in cattle.Type: ApplicationFiled: March 4, 2014Publication date: September 4, 2014Inventors: Anna ROSANDER, Märit PRINGLE
-
Publication number: 20140248271Abstract: This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein.Type: ApplicationFiled: February 6, 2014Publication date: September 4, 2014Applicant: OSCIENT PHARMACEUTICALS CORPORATIONInventors: Tim Keith, Randall Little, Paul Van Eerdewegh, Josée Dupuis, Richard Del Mastro, Jason Simon, Kristina Allen, Sunil Pandit
-
Publication number: 20140248631Abstract: The present invention relates a method for the diagnosis, prediction or risk stratification for mortality and/or disease outcome of a subject that has or is suspected to have sepsis, comprising determining the presence and/or level of antitrypsin (ATT) or fragments thereof in a sample taken from said subject and/or determining the presence and/or level of transthyretin (TTR) or fragments thereof, wherein the presence and/or level of ATT and/or TTR or fragments thereof is correlated with an increased risk of mortality and, wherein said increased risk of mortality and/or poor disease outcome is given if the level of ATT is below a certain cut-off value and/or the level of fragments thereof is above a certain cut-off value and/or said increased risk of mortality and/or poor disease outcome is given if the level of TTR is below a certain cut-off value and/or the level of fragments thereof is below a certain cut-off value.Type: ApplicationFiled: November 14, 2012Publication date: September 4, 2014Inventors: Michael Kiehntopf, Diana Schmerler, Thomas Deufel, Frank Brunkhorst
-
Publication number: 20140248261Abstract: An antibody against mutant ?-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of ?-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.Type: ApplicationFiled: September 9, 2011Publication date: September 4, 2014Applicants: NATIONAL CANCER CENTER, TRANS GENIC INC.Inventors: Shingo Shinagawa, Kazunari Ito, Yoshimi Tokashiki, Tomoaki Miyamoto, Kazufumi Honda, Tesshi Yamada
-
Patent number: 8821867Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: November 14, 2012Date of Patent: September 2, 2014Assignee: Pfizer IncInventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
-
Publication number: 20140243265Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: NOVARTIS AGInventors: Mara FORNARO, John XU, Yuan GAO, Rainer HILLENBRAND, Francois LEGAY, Daniela STOELLNER
-
Publication number: 20140242607Abstract: It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-?1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase ?1,6-N-acetylglucosaminyltransferase 5B as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.Type: ApplicationFiled: July 26, 2012Publication date: August 28, 2014Applicant: National Institute of Advanced Industrial Science and TechnologyInventors: Maki Sogabe, Tomomi Kubota, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hiromichi Sawaki, Hayao Nakanishi, Toru Nakanishi
-
Publication number: 20140243507Abstract: Provided is a method of screening a target-specific antibody for an antigen that undergoes structural change in a particular physiological condition.Type: ApplicationFiled: February 28, 2014Publication date: August 28, 2014Applicant: Samsung Electronics Co., Ltd.Inventors: Min-Kyung KIM, Jae-il Lee
-
Publication number: 20140242083Abstract: The invention provides anti-MCSP antibodies and methods of using the same.Type: ApplicationFiled: February 24, 2014Publication date: August 28, 2014Applicant: ROCHE GLYCART AGInventors: Thomas Hofer, Ralf Hosse, Ekkehard Moessner
-
Publication number: 20140243432Abstract: The presently-disclosed subject matter provides methods for diagnosing a cardiovascular disease in a subject by determining an amount of one or more peptide biomarkers disclosed herein in a biological sample from the subject. The presently-disclosed subject matter further provides methods for determining treatment efficacy and/or progression of a cardiovascular disease in a subject by measuring amounts of one or more of the biomarkers in a biological sample from the subject. The presently-disclosed subject matter also provides antibodies and kits for measuring the biomarkers.Type: ApplicationFiled: April 11, 2014Publication date: August 28, 2014Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Jon Klein, Michael L. Merchant, Rosemary Ouseph, Richard A. Ward
-
Publication number: 20140242085Abstract: As a result of the analysis by an SST-REX method so as to identify a target molecule for treating and testing an Aspergillus fumigatus infection, a YMAF1 protein has been found out, which is mainly localized in the cell wall of Aspergillus fumigatus. Moreover, it has been found out that YMAF1 protein-deficient Aspergillus fumigatus has reduced spore-forming ability and pathogenicity. Further, it has been found out that the survival rate of experimental mice having aspergillosis (invasive Aspergillus model mice) is improved by preparing and administering an antibody against the YMAF1 protein. Furthermore, it has been found out that Aspergillus fumigatus can be detected with a favorable sensitivity by an ELISA system using the antibody.Type: ApplicationFiled: August 12, 2011Publication date: August 28, 2014Applicants: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., NATIONAL INSTITUTE OF INFECTIOUS DISEASESInventors: Yoshitsugu Miyazaki, Satoshi Yamagoe, Masunori Kajikawa, Masahito Sugiura, Reiko Itoh, Hirotaka Kumagai
-
Publication number: 20140243506Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.Type: ApplicationFiled: October 19, 2012Publication date: August 28, 2014Inventors: Andreas Bültmann, Robert Mühlbacher, Teresa Garcia, Reginald Christophe Xavier Brys, Luc Nelles, Katja Conrath
-
Publication number: 20140242084Abstract: Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANGPTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated the disruption of endothelial continuity by directly interacting with three novel binding partners, integrin ?5?1, VEcadherin and claudin-5, in a temporally sequential manner, thus facilitating metastasis. We showed that cANGPTL4 binds and activates integrin ?5?1-mediated Rac1/PAK signaling to weaken cell-cell contacts. cANGPTL4 subsequently associated with and declustered VE-cadherin and claudin-5, leading to endothelial disruption. Interfering with the formation of these cANGPTL4 complexes delayed vascular disruption.Type: ApplicationFiled: August 8, 2012Publication date: August 28, 2014Applicant: NANYANG TECHNOLOGICAL UNIVERSITYInventor: Nguan Soon Tan
-
Publication number: 20140242071Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: ApplicationFiled: February 3, 2014Publication date: August 28, 2014Applicants: XOMA TECHNOLOGY LTD., NOVARTIS VACCINES AND DIAGNOSTICS INC.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Publication number: 20140242086Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.Type: ApplicationFiled: April 8, 2014Publication date: August 28, 2014Applicant: Incyte CorporationInventors: Preeti G. Lal, Y. Tom Tang, Gina A. Gorgone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice K. Au-Young, Henry Yue, Chandra S. Arvizu, Roopa M. Reddy, Jennifer L. Jackson, Olga Bandman